Cargando…

Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome

We aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in young people with Down syndrome (DS), and to compare their humoral immune response with those of the healthy controls (HC). Individuals with DS and HC received the BNT162b2 vaccine. Longitudinal blood samples were collecte...

Descripción completa

Detalles Bibliográficos
Autores principales: Valentini, Diletta, Cotugno, Nicola, Scoppola, Vittorio, Di Camillo, Chiara, Colagrossi, Luna, Manno, Emma Concetta, Perno, Carlo Federico, Russo, Cristina, Palma, Paolo, Rossi, Paolo, Villani, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836979/
https://www.ncbi.nlm.nih.gov/pubmed/35160144
http://dx.doi.org/10.3390/jcm11030694
_version_ 1784649810964381696
author Valentini, Diletta
Cotugno, Nicola
Scoppola, Vittorio
Di Camillo, Chiara
Colagrossi, Luna
Manno, Emma Concetta
Perno, Carlo Federico
Russo, Cristina
Palma, Paolo
Rossi, Paolo
Villani, Alberto
author_facet Valentini, Diletta
Cotugno, Nicola
Scoppola, Vittorio
Di Camillo, Chiara
Colagrossi, Luna
Manno, Emma Concetta
Perno, Carlo Federico
Russo, Cristina
Palma, Paolo
Rossi, Paolo
Villani, Alberto
author_sort Valentini, Diletta
collection PubMed
description We aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in young people with Down syndrome (DS), and to compare their humoral immune response with those of the healthy controls (HC). Individuals with DS and HC received the BNT162b2 vaccine. Longitudinal blood samples were collected on the day of vaccination, twenty-one days after the first dose, seven days after the second dose, and six months after the first dose. Both the local and systemic adverse events reported by participants were mild. Pain at the injection site was the most reported local adverse event, while fever was the systemic adverse event. Humoral responses showed a significant increase of anti-S and anti-S trimeric antibody (Ab) levels after both doses of vaccine in both groups. In comparison with HC, Ab levels in individuals with DS were similar at T21, but significantly lower, both in terms anti-S and anti-S trimeric, at T28 (respectively p = 0.0003 and p = 0.0001). At T180 both groups showed a significant reduction of anti-S trimeric Ab levels compared to T28 (p = 0.0004 and p < 0.0001 for DS and HC, respectively). Individuals with DS exhibit a good humoral response to the BNT162b2 vaccine; however, similarly to in HC, the immune response wanes over time.
format Online
Article
Text
id pubmed-8836979
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88369792022-02-12 Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome Valentini, Diletta Cotugno, Nicola Scoppola, Vittorio Di Camillo, Chiara Colagrossi, Luna Manno, Emma Concetta Perno, Carlo Federico Russo, Cristina Palma, Paolo Rossi, Paolo Villani, Alberto J Clin Med Brief Report We aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in young people with Down syndrome (DS), and to compare their humoral immune response with those of the healthy controls (HC). Individuals with DS and HC received the BNT162b2 vaccine. Longitudinal blood samples were collected on the day of vaccination, twenty-one days after the first dose, seven days after the second dose, and six months after the first dose. Both the local and systemic adverse events reported by participants were mild. Pain at the injection site was the most reported local adverse event, while fever was the systemic adverse event. Humoral responses showed a significant increase of anti-S and anti-S trimeric antibody (Ab) levels after both doses of vaccine in both groups. In comparison with HC, Ab levels in individuals with DS were similar at T21, but significantly lower, both in terms anti-S and anti-S trimeric, at T28 (respectively p = 0.0003 and p = 0.0001). At T180 both groups showed a significant reduction of anti-S trimeric Ab levels compared to T28 (p = 0.0004 and p < 0.0001 for DS and HC, respectively). Individuals with DS exhibit a good humoral response to the BNT162b2 vaccine; however, similarly to in HC, the immune response wanes over time. MDPI 2022-01-28 /pmc/articles/PMC8836979/ /pubmed/35160144 http://dx.doi.org/10.3390/jcm11030694 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Valentini, Diletta
Cotugno, Nicola
Scoppola, Vittorio
Di Camillo, Chiara
Colagrossi, Luna
Manno, Emma Concetta
Perno, Carlo Federico
Russo, Cristina
Palma, Paolo
Rossi, Paolo
Villani, Alberto
Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
title Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
title_full Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
title_fullStr Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
title_full_unstemmed Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
title_short Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
title_sort safety and long-term immunogenicity of bnt162b2 vaccine in individuals with down syndrome
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836979/
https://www.ncbi.nlm.nih.gov/pubmed/35160144
http://dx.doi.org/10.3390/jcm11030694
work_keys_str_mv AT valentinidiletta safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome
AT cotugnonicola safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome
AT scoppolavittorio safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome
AT dicamillochiara safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome
AT colagrossiluna safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome
AT mannoemmaconcetta safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome
AT pernocarlofederico safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome
AT russocristina safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome
AT palmapaolo safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome
AT rossipaolo safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome
AT villanialberto safetyandlongtermimmunogenicityofbnt162b2vaccineinindividualswithdownsyndrome